AVklapid

AVklapid is a medication used to treat high cholesterol levels, specifically to lower levels of LDL cholesterol, also known as "bad" cholesterol. It belongs to a class of drugs called PCSK9 inhibitors, which work by blocking a protein called proprotein convertase subtilisin/kexin type 9 (PCSK9). This protein plays a role in the body's natural process of breaking down LDL cholesterol, and by inhibiting it, AVklapid helps to increase the body's ability to clear LDL cholesterol from the bloodstream.

AVklapid is typically prescribed as an adjunct to diet and exercise, and is often used in patients who have not responded adequately to other cholesterol-lowering medications. It is available in tablet form and is taken orally once daily. Common side effects of AVklapid may include muscle pain, back pain, and injection site reactions. Serious side effects are rare but can include muscle inflammation and kidney problems.

AVklapid was approved by the U.S. Food and Drug Administration (FDA) in 2015 and is marketed under the brand name Repatha. It is manufactured by Amgen, a biotechnology company. The drug has been shown to be effective in reducing LDL cholesterol levels and has been well-tolerated in clinical trials. However, as with any medication, patients should discuss the potential benefits and risks with their healthcare provider before starting treatment with AVklapid.